ICU Medical narrows FY25 EPS view to $6.85-$7.15 from $6.55-$7.25

Consensus $6.64. The company said, “The Company is updating the estimate of the range of its full year 2025 guidance, inclusive of the previously disclosed impact of the IV Solutions joint venture, of adjusted EBITDA from a range of $380 million to $405 million to a range of $380 million to $390 million and diluted earnings per share from a range of $6.55 to $7.25 to a range of $6.85 to $7.15.”